Manijeh Goldberg, PH.D.

Manijeh Goldberg, PH.D., M.B.A., M.S.

CHIEF EXECUTIVE OFFICER

Manijeh is the Founder and CEO of Privo, a biopharmaceutical company revolutionizing localized drug delivery for oncology. With over 25 years of experience spanning large corporations and startups (one acquired for $475M), she brings a proven track record of leadership and innovation.

As CEO, Manijeh has cultivated strategic partnerships, including close collaborations with the National Cancer Institute (NCI) and National Institute of Dental and Craniofacial Research (NIDCR). She successfully lobbied for Privo’s flagship product, PRV111, to be included in an NIH-funded clinical study and has overseen its development into second-generation products. Currently, PRV111 (a topical treatment for early carcinomas) and PRV211 (designed for intraoperative use to reduce residual cancer cells) are in human clinical trials, while PRV131, an intratumoral injectable for solid tumors, is being studied in companion animals, showing promising results.

Manijeh is driving Privo’s growth through business development, clinical trial execution, and the expansion of its transformative pipeline. She holds a Ph.D. in Biomedical Engineering, an MS in Health Sciences and Technology from Harvard Medical School, an MBA from MIT Sloan, and an MS in Computer Science and Mathematics.


Contact Us
close slider

Contact Us